CAS: 223532-02-3

CPA inhibitor

CPA inhibitor (Carboxypeptidase inhibitor) is a potent carboxypeptidase A (CPA) inhibitor with a Ki of 0.32 μM.

CPA inhibitor is a biochemical compound designed to selectively inhibit carboxypeptidase A (CPA), a metalloenzyme implicated in various physiological and pathological processes. It is typically sourced from synthetic chemical libraries or derivative natural compounds, characterized by their high specificity and affinity for the active site of CPA. The mode of action involves binding to the metalloenzyme’s active site, thereby obstructing substrate access and reducing enzymatic activity. Inhibition of CPA can be crucial for research purposes, including the study of protein and peptide processing, regulation of blood pressure, and understanding cancer metastasis. Additionally, CPA inhibitors hold potential therapeutic value in conditions where modulation of peptide hormone processing is beneficial. Their application extends to drug discovery, where they serve as tool compounds for elucidating the role of CPA in disease pathways and as lead compounds for developing novel therapies. Scientists employ these inhibitors to dissect the molecular underpinnings of enzymatic regulation and to identify new therapeutic targets within the protease family.